119 HR 679
To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.
Latest Action
Referred to the House Committee on Energy and Commerce.
2025-01-23
Read the Bill
Primary sources on Congress.gov:
Cosponsors (showing 10 of 18)
R · Hern, Kevin (Oklahoma)R · Bost, Mike (Illinois)R · Miller, Mary E. (Illinois)R · Weber, Randy K. Sr. (Texas)R · Babin, Brian (Texas)R · Moolenaar, John R. (Michigan)R · Webster, Daniel (Florida)R · Baird, James R. (Indiana)R · Higgins, Clay (Louisiana)R · Feenstra, Randy (Iowa)Federal Agency Posts Matching This Bill
Posts from federal agencies in the last 24 hours that match this bill's identifier or title keywords. Grouped by voice class — executive framing carries the administration's perspective; regulators speak to implementation; oversight bodies aim for neutrality. Read across, not just within, a single voice class.
Independent oversight (CBO, GAO, Federal Register, Congress.gov)
Non-partisan analysis: CBO cost scoring, GAO investigations, Federal Register rule publications, and Congress.gov legislative tracking. The closest thing to neutral framing on a bill's likely effect.
Nuclear Security Enterprise: Strategic Partnership Projects Can Support Mission, Operations, and Research
What GAO Found The National Nuclear Security Administration (NNSA)—a separately organized agency within the Department of Energy (DOE)—and its eight contractor-managed and -operated sites engage in Strategic Partnership Projects (SPP). These projects allow NNSA sites to perform w
Read on gao.gov →Most-Viewed Bills - Week of September 6, 2026
H.R.6509 [119th] - SAFE Drugs Act of 2025 H.R.6500 [119th] - Continuing Appropriations and Extensions Act, 2027 H.Res.1490 [119th] - Providing for the condemnation and denouncement of socialism in all its forms, and for other purposes. H.R.4795 [119th] - Protect Economic and Acad
Read on congress.gov →Markets vs Bill
Cite this page
APA
Apprised.news. (n.d.). 119 HR 679: To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.. Retrieved 2026-09-11, from https://apprised.news/bill/119hr679
MLA
"119 HR 679: To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.." Apprised.news. Web. 2026-09-11. <https://apprised.news/bill/119hr679>.
Chicago
"119 HR 679: To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.." Apprised.news. Accessed 2026-09-11. https://apprised.news/bill/119hr679.
BibTeX
@misc{apprised_119_hr_679_to_nullify_the_modifications_,
title = {119 HR 679: To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.},
publisher = {Apprised.news},
url = {https://apprised.news/bill/119hr679},
note = {Accessed 2026-09-11}
}